Ulka Vaishampayan, MBBS

Ulka Vaishampayan, MBBS

Professor of Internal Medicine
Director, Phase I Program
Rogel Cancer Center
University of Michigan
Ann Arbor, MI

Related Videos

Can you comment on the enduring responses (long term remissions) observed with nemvaleukin in ARTISTRY-1 and its manageable safety profile, and how it is unique among novel, engineered cytokine fusion proteins developed in the immunotherapy space? Video

Can you comment on the enduring responses (long term remissions) observed with nemvaleukin in ARTISTRY-1 and its manageable safety profile, and how it is unique among novel, engineered cytokine fusion proteins developed in the immunotherapy space?

Can you summarize the key findings from the ARTISTRY-1 trial, with a special emphasis on signals that Part A of the trial provided regarding the potential efficacy and safety of nemvaleukin within the context of a small dose escalation study? Video

Can you summarize the key findings from the ARTISTRY-1 trial, with a special emphasis on signals that Part A of the trial provided regarding the potential efficacy and safety of nemvaleukin within the context of a small dose escalation study?

Given the ARTISTRY-1 trial, how would you envision the role of nemvaleukin within the larger context of immunotherapy? How should cytokines be sequenced in the therapeutic pathway for refractory patients such as those evaluated in ARTISTRY-1? Video

Given the ARTISTRY-1 trial, how would you envision the role of nemvaleukin within the larger context of immunotherapy? How should cytokines be sequenced in the therapeutic pathway for refractory patients such as those evaluated in ARTISTRY-1?

Can you summarize the design of the ARTISTRY-1 trial with nemvaleukin, including strategies/phases incorporated to evaluate the potential effectiveness, dosing, and combinatorial effects of nemvaleukin with ICIs in the setting of solid tumors? Video

Can you summarize the design of the ARTISTRY-1 trial with nemvaleukin, including strategies/phases incorporated to evaluate the potential effectiveness, dosing, and combinatorial effects of nemvaleukin with ICIs in the setting of solid tumors?

Although no biomarkers have yet been identified to predict optimal patient cohorts of nemvaleukin-based immunotherapy, do you envision a pathway to identifying biomarkers in the future? Video

Although no biomarkers have yet been identified to predict optimal patient cohorts of nemvaleukin-based immunotherapy, do you envision a pathway to identifying biomarkers in the future?

Can you drill down into the results for Part B of the ARTISTRY-1 study and share results in terms of partial and/or complete responses observed in different tumor subtypes, including mucosal melanoma, advanced kidney cancer, and ovarian carcinoma? Video

Can you drill down into the results for Part B of the ARTISTRY-1 study and share results in terms of partial and/or complete responses observed in different tumor subtypes, including mucosal melanoma, advanced kidney cancer, and ovarian carcinoma?

So that our learners can better understand your experience and expertise in cancer immunotherapy and clinical trial design, can you share your current role and affiliations and how you became involved in the phase 1 nemvaleukin trial ARTISTRY-1? Video

So that our learners can better understand your experience and expertise in cancer immunotherapy and clinical trial design, can you share your current role and affiliations and how you became involved in the phase 1 nemvaleukin trial ARTISTRY-1?

Although nemvaleukin is being investigated in the context of ICI-refractory disease, what might its potential role be in chemotherapy-refractory disease? Video

Although nemvaleukin is being investigated in the context of ICI-refractory disease, what might its potential role be in chemotherapy-refractory disease?

What specific, actionable signals emerged from results of Part C of the ARTISTRY-1 trial with respect to partial/complete and/or enduring responses employing a combination of the cytokine fusion protein nemvaleukin in combination with ICIs? Video

What specific, actionable signals emerged from results of Part C of the ARTISTRY-1 trial with respect to partial/complete and/or enduring responses employing a combination of the cytokine fusion protein nemvaleukin in combination with ICIs?